CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Certain Confidential • September 25th, 2020 • Praxis Precision Medicines, Inc. • Pharmaceutical preparations • Delaware
This RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of the 11th day of September, 2019 (the “Effective Date”) by and between Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Ionis”), and Praxis Precision Medicines, Inc., a Delaware corporation with its principal place of business at One Broadway Street, 16th Floor, Cambridge, MA 02142 (“Praxis”). Praxis and Ionis each may be referred to herein individually as a “Party” or collectively as the “Parties”
MASTER SERVICES AGREEMENTCertain Confidential • October 10th, 2023 • Docola, Inc. • Services-computer processing & data preparation • Quebec
This Agreement is effective as of December 9, 2021 by and between AbbVie Corporation, a corporation under the laws of Canada and having its principal place of business at 8401 Trans- Canada Highway, St-Laurent, Quebec, Canada H4S 1Z1 (“AbbVie”) and Docola Inc., having a mailing address of 801 West Bay Dr, Largo, FL, 33770-3220 (“Service Provider”, collectively with AbbVie, the “Parties” or individually a “Party”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Certain Confidential • September 28th, 2023 • StoneBridge Acquisition Corp. • Services-prepackaged software
This Technology Cooperation Agreement (“Agreement”) is made on this 2 June 2020 2020 by and between: Perjanjian Kerja Sama Teknologi (“ Perjanjian ”) ini dibuat pada 2 Juni 2020 ini oleh dan antara:
AMENDMENT No 1 TO THE LICENSE AGREEMENT EFFECTIVE THE 17TH DAY OF NOVEMBER 2015 BETWEEN STANFORD UNIVERSITY AND AKOYA BIOSCIENCESCertain Confidential • March 26th, 2021 • Akoya Biosciences, Inc. • Laboratory analytical instruments
Effective the 18th day of November, 2016, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Akoya Biosciences, Inc. (“AKOYA”), a corporation having a principal place of business at 360 Post Street, Suite 601, San Francisco, CA, agree as follows:
Amended Capital Increase AgreementCertain Confidential • May 10th, 2017 • BeiGene, Ltd. • Pharmaceutical preparations
BeiGene (Hong Kong) Co., Limited, a limited liability company incorporated under the laws of Hong Kong, with its registered place of business at 13/F, Gloucester Tower, The Landmark, 15 Queen’s Road, Central, Hong Kong (“BeiGene”)
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT...Certain Confidential • February 7th, 2023 • TRxADE HEALTH, INC • Wholesale-drugs, proprietaries & druggists' sundries • Delaware
THIS VOLUNTARY WITHDRAWAL AND RELEASE AGREEMENT (the “Agreement”) is made and entered into as of date last written below (the “Effective Date”) by and among SOSRx, LLC, a Delaware limited liability company (the “Company”), Exchange Health, LLC, a Michigan limited liability company (“Exchange Health” or “EH”), and TRxADE HEALTH, INC., a Delaware corporation (the “Withdrawing Member” or “TH”), concerning the voluntary withdrawal of the Withdrawing Member from the Company. Capitalized terms used herein but not otherwise defined shall have the meanings assigned thereto in the Limited Liability Company Agreement of the Company, dated as of February 15, 2022 (the “LLC Agreement”). The Withdrawing Member, the Company and Exchange Health are referred to herein each as a “Party” and collectively the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[...***...].” A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE U.S. SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION...Certain Confidential • May 10th, 2017 • BeiGene, Ltd. • Pharmaceutical preparations
WHEREAS, BeiGene (Hong Kong) Co., Limited., is a limited liability company established under the laws of the Hong Kong Special Administrative Region and registered in 13/F, Gloucester Tower, The Landmark, 15 Queen’s Road Central, Hong Kong (“Party A”);
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Certain Confidential • October 5th, 2021 • Capstar Special Purpose Acquisition Corp. • Pharmaceutical preparations • New York
Pharmaceutical Distribution Agreement (“Agreement”) dated as of Feb 12, 2020 (the “Effective Date”) between Gelesis, Inc., a Delaware Corporation (“Manufacturer”) and Specialty Medical Drugstore, LLC, an Ohio limited liability corporation dba GoGoMeds (“Pharmacy”) and, together with Gelesis, the “[__]” and together with GoGoMeds the “Parties”).
EXCLUSIVE LICENSE AGREEMENT Johns Hopkins University and Capricor, Inc. JHU Agreement Number A38423Certain Confidential • August 13th, 2021 • Capricor Therapeutics, Inc. • Pharmaceutical preparations • Maryland
This AGREEMENT is entered into by and between the Johns Hopkins University (“JHU”), a Maryland corporation having an address at 3400 N. Charles Street, Baltimore, Maryland, 21218-2695 and, Capricor, Inc. (“LICENSEE”), a Delaware corporation having an address at 8840 Wilshire Blvd., 2nd Floor, Beverly Hills, California 90211 and is effective on the 15 day of April, 2021 (“EFFECTIVE DATE”).
First Amendment to Patent License AgreementCertain Confidential • May 28th, 2020 • Cabaletta Bio, Inc. • Biological products, (no disgnostic substances)
This First Amendment (this “First Amendment”) to the Amended and Restated License Agreement (the “CARLA”) effective as of May 27, 2020, is made by and between The Trustees of the University of Pennsylvania (“Penn”) and Cabaletta Bio, Inc. (“Licensee”) and The Children’s Hospital of Philadelphia (“CHOP”) and amends the CARLA between the Parties, dated July 23, 2019. Capitalized terms used herein shall have the meanings given in the CARLA.
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “***”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING...Certain Confidential • January 25th, 2008 • Phenomix CORP
This FIRST AMENDMENT TO THE SETTLEMENT AGREEMENT AND RELEASE is entered into as of June 28, 2007 and is effective as if entered into on August 1, 2006 (the “EFFECTIVE DATE”), by, between and among ACTIVX BIOSCIENCES, INC., a Delaware corporation (“ActivX”), and DAVID CAMPBELL, an individual (“Campbell”), DAVID WINN, an individual (“Winn”), on the one hand, JUAN BETANCORT, an individual (“Bettancourt”) and PHENOMIX CORPORATION, a Delaware corporation (“Phenomix”), on the other hand, (Campbell, Winn, Betancort and Phenomix are sometimes referred to as the “Phenomix Parties”) shall amend the aforementioned SETTLEMENT AND RELEASE AGREEMENT in the following respect:
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Certain Confidential • March 15th, 2024 • ATN International, Inc. • Telephone communications (no radiotelephone)
This Fourth Amendment to the Network Build and Maintenance Agreement (“Fourth Amendment”) is entered into as of the 21st day of December, 2023 and is effective as of the 30th day of September, 2023 (the “Effective Date”) by and between Commnet Wireless, LLC, a Delaware limited liability company, on behalf of itself and its Affiliates (collectively and hereinafter referred to as “Vendor”), and AT&T Mobility, LLC, a limited liability company organized under the laws of Delaware (“AT&T Mobility”). Each of Carrier and AT&T Mobility may be referred to in the singular as “Party” or in the plural as “Parties.”
DEVELOPMENT, COMMERCIALIZATION AND SUPPLY AGREEMENT DATED AS OF NOVEMBER 3, 2017 BY AND BETWEEN VASCULAR BIOGENICS LTD. AND NANOCARRIER CO., LTD.Certain Confidential • March 15th, 2018 • Vascular Biogenics Ltd. • Pharmaceutical preparations • New York
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. ACOMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THESECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIALTREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,AS AMENDED.
LICENSE AND SUPPLY AGREEMENTCertain Confidential • November 13th, 2017 • BeiGene, Ltd. • Pharmaceutical preparations • New York
This Agreement dated as of July 5, 2017 (the “Execution Date”) and effective on the Effective Date (as defined below), is entered into between Celgene Logistics Sàrl, a corporation incorporated under the laws of Switzerland, with registered offices at Route de Perreux 1, 2017 Boudry Switzerland (“Celgene”), and BeiGene, Ltd., a corporation organized under the laws of the Cayman Islands having an address of c/o Mourant Ozannes Corporate Services, (Cayman) Limited 94 Solaris Avenue, PO Box 1348, Grand Cayman KY1-1108, Cayman Islands GB (“BeiGene").
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[...***...].” A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE U.S. SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION...Certain Confidential • May 10th, 2017 • BeiGene, Ltd. • Pharmaceutical preparations
Guangzhou GET Technology Development Co., Ltd., a limited liability company incorporated under the laws of the People’s Republic of China (the “PRC” or “China”), with its registered place of business at Room 901, No.237 Science Avenue, Science City, Guangzhou High-tech Industrial Development Zone, the PRC (“GET”); and
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Certain Confidential • June 23rd, 2020 • Compass Therapeutics, Inc. • Blank checks • New York
This Amended and Restated Collaboration Agreement (the “Agreement”), dated February 11, 2015, amends and restates the Collaboration Agreement (the “Original Agreement”) made as of October 16, 2014 (the “Effective Date”) and amended as of December 9, 2014, by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”) and Kairos Biologics Foundation LLC, a Delaware limited liability company having an address at 44 South Main Street, Hanover, NH 03755 (“Kairos”).
EXCLUSIVE LICENSE AGREEMENT BETWEEN AKOYA BIOSCIENCES, INC. AND UNIVERSITY OF WASHINGTON FOR TECHNOLOGY FOR MOLECULAR PROFILING OF CELLS AND TISSUE SPECIMENS UW COMOTION AGREEMENT 43158ACertain Confidential • March 26th, 2021 • Akoya Biosciences, Inc. • Laboratory analytical instruments • Washington
This exclusive patent license agreement (this “Agreement”), effective as of June 26, 2018 (the “Effective Date”), is made and entered into between the University of Washington, a public institution of higher education and an agency of the state of Washington, (“University”), and Akoya Biosciences, Inc., a Delaware (“Company”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT...Certain Confidential • March 14th, 2022 • Vertex Energy Inc. • Petroleum refining • Texas
This Agreement effective July 1, 2012, is between KMTEX LLC, a Texas Limited Liability Corporation, having an office at 333 North Sam Houston Parkway, East, Suite 1250, Houston, Texas 77060 (hereafter called MANUFACTURER) and Vertex Energy, Inc., a Nevada Corporation having an office for the purposes of this Agreement at 200 Atlantic Pipeline Road, Baytown, TX 77520 (hereafter called CUSTOMER); also collectively referred to as the “Parties”.
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II)WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED....Certain Confidential • January 31st, 2024 • Masterworks 210, LLC • Retail-retail stores, nec • New York
Selling price and Payment: A buyer may be offered extended payment terms of up to thirty (30) calendar days from the date of receipt of an invoice by Consignee. Payment to Level will occur within five (5) business days of Consignee’s receipt of the purchase price in full.
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Certain Confidential • December 14th, 2021 • Vaccitech PLC • Pharmaceutical preparations • Delaware
This Agreement and Plan of Merger and Reorganization (this “Agreement”) is made and entered into as of December 9, 2021 (the “Agreement Date”), by and among Vaccitech PLC, a corporation organized under the laws of England and Wales (“Acquirer”), VA Merger Sub 1 Inc., a Delaware corporation and a direct, wholly owned subsidiary of Acquirer (“Merger Sub 1”), VA Merger Sub 2 Inc., a Delaware corporation and a direct, wholly owned subsidiary of Acquirer (“Merger Sub 2” and together with Merger Sub 1, the “Merger Subs”), Avidea Technologies, Inc., a Delaware corporation (the “Company”), and Benjamin Eisler, an individual, as the Securityholder Agent (as defined below). Certain other terms used herein are defined in Exhibit A.
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Certain Confidential • March 26th, 2021 • Akoya Biosciences, Inc. • Laboratory analytical instruments • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Akoya Biosciences, Inc. (“AKOYA”), a Delaware corporation having a principal place of business at 360 Post Street, Suite 601, San Francisco, California, is effective on the 17th day of November, 2015 (“Effective Date”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS...Certain Confidential • March 16th, 2023 • Cabaletta Bio, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Development, Manufacturing and Testing Services Agreement (the "Services Agreement") is made and entered into as of January 11, 2021 (the "Effective Date") by and between WuXi Advanced Therapies Inc., a corporation organized under the laws of Delaware with offices located at 4751 League Island Blvd., Philadelphia, Pennsylvania 19112 ("WuXi"), and Cabaletta Bio, Inc., a company organized under the laws of Delaware with office located at 2929 Arch Street, Suite 600, Philadelphia, PA 19104 ("Customer"). Customer and WuXi are referred to herein individually as a "Party" and collectively as the "Parties".
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS...Certain Confidential • March 17th, 2022 • Cabaletta Bio, Inc. • Biological products, (no disgnostic substances) • England and Wales
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Certain Confidential • November 4th, 2020 • ATN International, Inc. • Telephone communications (no radiotelephone)
This First Amendment to Network Build and Maintenance Agreement (the “First Amendment”) is entered into as of the 6th day of August, 2020 and effective as of the 1st day of July, 2020 (the “First Amendment Effective Date”), by and between Commnet Wireless, LLC, a Delaware limited liability company on behalf of itself and its Affiliates (hereinafter referred to as “Vendor”), and AT&T Mobility LLC, a Delaware limited liability company on behalf of itself and its Affiliates (“AT&T”), each of which may be referred to in the singular as a “Party” or in the plural as the “Parties.”
